The thesis

ImmunityBio is a clinical-stage biotech firm with 93.9% revenue growth, but a -598.6% net margin. Its Decifer score is 34, indicating watchlist status. Analyst consensus is BUY, despite a -10.9x P/E ratio and DCF intrinsic value of -$20. The high gross margin of 94.6% suggests potential for scalability.

Why now

The recent Nasdaq gains and ISM manufacturing PMI slip in September create a risk-off environment, making ImmunityBio's risk profile more relevant. The USA Unemployment Rate increase to 4.2% in September may also impact investor sentiment towards high-risk investments like biotech firms.

What to watch

Investors should monitor ImmunityBio's upcoming financial reports for signs of improving net margin and cash flow. The company's progress in clinical trials and regulatory approvals will also be crucial in determining its investment potential over the next 1-3 quarters.

Key risks

The company's negative net margin and DCF intrinsic value of -$20 pose significant valuation risks. Execution risk is also high, given the need to translate revenue growth into profitability.

Theme exposure